1. Scrip
  2. >>R&D
  3. >>Clinical Trials

J&J Gets Two Studies Closer To $5bn Sales Goal For Nipocalimab

Firm Reports Positive Data In Myasthenia Gravis And Sjögren’s

 
• By Alaric DeArment

Analysts said full data from the VIVACITY study in generalized myasthenia gravis would be key to determining the drug’s competitive profile against approved anti-FcRn agents.

• Source: Shutterstock

Johnson & Johnson is entering the ring of treatments for generalized myasthenia gravis (gMG) with topline Phase III results for nipocalimab, but it is an increasingly competitive field with multiple approved drugs already, meaning that detailed data will make it easier to sort out how the drug stacks up – and how much of a contribution gMG makes to J&J’s “pipeline-in-a-product” strategy.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Moderna Punts On US Vaccine Policy Changes, Will Focus More On Cancer

 
• By Joseph Haas

On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.

Could There Be A Cure For Cardiometabolic Disease? Novo Nordisk Foundation Wants To Help Academics Find Out

 
• By Andrew McConaghie

The not-for-profit’s senior vice president Martin Ridderstråle explains how it is expanding grants for basic research to improve "human and planetary" health.

GSK Talks Up Nucala COPD Hospitalization Data In Challenge To Dupixent

 
• By Kevin Grogan

As the PDUFA date for the UK major’s IL-5 inhibitor draws close.